If you are weighing up whether stepping up to Wegovy 7.2 mg is worth it, the honest answer depends on numbers most comparisons gloss over: not just an average weight loss figure, but how many people actually reached meaningful thresholds, and what you trade for that extra effect. Here is what the trial behind this dose actually found.
What Was The STEP UP Trial, Exactly?
The STEP UP trial followed 1,407 adults with obesity (BMI 30 or above) who did not have type 2 diabetes. It was a 72-week, randomised, double-blind trial comparing Wegovy 7.2 mg with the standard 2.4 mg dose and placebo.
Participants were recruited from 95 hospitals, specialist clinics and medical centres across 11 countries. They were randomly assigned to one of the three groups in a 5:1:1 ratio, with all groups also receiving lifestyle support. A separate companion study, STEP UP T2D, looked at the same dose comparison in 512 adults with obesity and type 2 diabetes.
How Does 7.2 mg Compare With 2.4 mg And Placebo?
Clearly